Edwards Lifesciences Corporation $EW Stock Position Lifted by Simplify Asset Management Inc.

Simplify Asset Management Inc. lifted its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 92.3% in the 4th quarter, HoldingsChannel reports. The firm owned 19,338 shares of the medical research company’s stock after purchasing an additional 9,284 shares during the quarter. Simplify Asset Management Inc.’s holdings in Edwards Lifesciences were worth $1,649,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Edwards Lifesciences by 0.5% in the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock worth $5,472,147,000 after purchasing an additional 365,581 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Edwards Lifesciences by 4.9% in the third quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock worth $1,617,959,000 after purchasing an additional 977,933 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Edwards Lifesciences by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock worth $1,478,425,000 after purchasing an additional 1,423,365 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after purchasing an additional 4,108,270 shares in the last quarter. Finally, Holocene Advisors LP grew its stake in shares of Edwards Lifesciences by 0.9% in the third quarter. Holocene Advisors LP now owns 4,746,694 shares of the medical research company’s stock worth $369,150,000 after purchasing an additional 42,717 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on EW shares. UBS Group reaffirmed a “neutral” rating and set a $94.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Truist Financial set a $90.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Evercore reaffirmed an “outperform” rating and set a $93.00 target price on shares of Edwards Lifesciences in a research note on Friday, April 24th. Finally, Wolfe Research raised Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price for the company in a research note on Wednesday, April 1st. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.65.

Edwards Lifesciences Stock Performance

Shares of EW opened at $85.93 on Monday. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $87.89. The company has a 50-day moving average of $81.42 and a two-hundred day moving average of $82.89. The stock has a market cap of $49.48 billion, a price-to-earnings ratio of 45.71, a PEG ratio of 2.15 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the company posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. This represents a 24.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 9,968 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $82.07, for a total value of $818,073.76. Following the completion of the sale, the vice president directly owned 22,798 shares of the company’s stock, valued at approximately $1,871,031.86. This represents a 30.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 106,684 shares of company stock valued at $8,811,739. Corporate insiders own 0.31% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.